fucosylated autologous bone marrow mesenchymal stem cells

Fucosylated autologous bone marrow mesenchymal stem cells are **mesenchymal stem cells (MSCs) isolated from a patient's own bone marrow**, which are then engineered or chemically modified to express higher levels of cell-surface fucose residues (a process known as fucosylation). The goal of this modification is to enhance the cells’ **homing efficiency to target tissues**, particularly in regenerative medicine applications, by improving their interaction with selectins and adhesion molecules on the endothelium. As with all MSCs, these cells are multipotent and can differentiate into various mesenchymal lineages (osteoblasts, chondrocytes, adipocytes) and possess immunomodulatory, anti-inflammatory, and regenerative properties. Fucosylated MSCs are an investigational cell therapy, not standard of care, and have been studied primarily in **preclinical models** and early-phase clinical studies for applications such as tissue repair, cardiovascular disease, graft-versus-host disease, and other immune-mediated or degenerative conditions. The autologous nature reduces immunogenicity and the risk of rejection. Fucosylation is intended to improve their therapeutic efficacy over unmodified MSCs by targeting and retaining transplanted cells in injured or inflamed tissues.

Other names

fucosylated autologous bone marrow-derived mesenchymal stem cellsfucosylated autologous BMSCfucosylated autologous BM-MSCs